Results 191 to 200 of about 51,890 (248)

Prospective implementation of the HCT frailty scale in adults with lymphoproliferative syndromes candidates for autologous haematopoietic stem cell transplantation: Results from a multicentre GETH‐TC study

British Journal of Haematology, EarlyView.
Summary This prospective study evaluated the incidence and dynamics of frailty in 156 adults with lymphoproliferative syndromes undergoing autologous haematopoietic stem cell transplantation (HSCT). Frailty was assessed using the haematopoietic cell transplantation (HCT) frailty scale in patients from 15 Spanish institutions at initial consultation ...
Javier Cornago, Mónica Baile, Marina Acera, Laura Fox, María del Mar Pérez‐Artigas, Ana Santamaría, María del Carmen Quintela, Andrés Sánchez‐Salinas, Joaquina M. Salmerón, Verónica Illana, Zahra Abdallahi‐Lefdil, Laura Pardo, Laura Solán, José Luis López‐Lorenzo, Sara Fernández‐Luis, Leddy Patricia Vega, Sara Villar, Patricia Beorlegui‐Murillo, Mónica Molina, Albert Esquirol, Isabel Izquierdo, Julia Ribes, Alberto Mussetti, Esperanza Lavilla, Olga Alda, Javier López‐Marín, Leyre Bento, Silvia Filaferro, Pascual Balsalobre, Anna Sureda, María Queralt Salas   +30 more
wiley   +1 more source

Phase I clinical study of humanized BCMA-single-domain antibodies targeting CAR-T in patients with relapsed or refractory multiple myeloma

Cancer Biology & Medicine
Gaofeng Zheng, Ruyi Xu, Heng Mei, Xiaoyan Han, Donghua He, Yanling Weng, Cheng Wen, Zhuoxiao Cao, Zhen Cai   +8 more
doaj   +1 more source

Restoring sensitivity to daratumumab with all-transretinoic acid in a patient with daratumumab-refractory multiple myeloma: A case report and review of the literature

Current Problems in Cancer: Case Reports
Noa Biran, David H. Vesole, Harsh Parmar, Pooja Phull, Susan Kumka, Kimberley Doucette, Joshua Zenreich, Bianca DeAgresta, Alexandra Della Pia, Lisa Biamonte, Martha Campanaro, Trina McClendon, Samanta BaboolallAracena, Palka Anand, Adolfo Aleman, Monique Pace, Genevieve Breeze, Kristin Ivanovski, Marie Layton, David S. Siegel   +19 more
doaj   +1 more source

Cesni‐cel (ARI0002h) in ultra‐high‐risk multiple myeloma with plasma cell leukaemia or central nervous system involvement

British Journal of Haematology, EarlyView.
ARI0002h induced response in 15/17 patients with plasma cell leukaemia (PCL)/central nervous system (CNS)‐multiple myeloma (MM) (87% achieved ≥ very good partial response [VGPR]) with a median progression‐free survival (PFS)/overall survival (OS) of 10.5 and 15.9 months respectively.
Carlos Jimenez‐Mira, Natalia Tovar, Núria Martínez‐Cibrián, Verónica González‐Calle, Nil Albiol, Nieves López‐Muñoz, Aina Oliver‐Caldés, Azucena González, José Miguel Mateos, Marta Español‐Rego, Laura Rosiñol, Manel Juan, Paola Charry, José María Sanchez‐Pina, Sergio Navarro, Daniel Munárriz, Lucía López‐Corral, Valentín Ortiz‐Maldonado, Sara Varea, Eulalia Olesti, Julio Delgado, Álvaro Urbano‐Ispizua, Joaquín Martínez‐López, María Victoria Mateos, Luis Gerardo Rodríguez‐Lobato, Carlos Fernández de Larrea   +25 more
wiley   +1 more source

Clinical and immunological effects of adding cyclophosphamide to pomalidomide–dexamethasone in relapsed‐refractory multiple myeloma: The randomized MUKseven trial

British Journal of Haematology, EarlyView.
Summary There is an ongoing need for accessible combination therapies for patients with relapsed‐refractory multiple myeloma (RRMM), alongside a growing interest in understanding their immunological effects, particularly on T‐cell populations. Myeloma UK (MUK) MUKseven (NCT02406222) was an academic, UK multicentre randomized controlled, open‐label ...
Andrew Hall, James Croft, Katrina Walker, Kevin Boyd, Sadie Roberts, Amy Holroyd, Mamta Garg, Elsa Ferris, Gordon Cook, William E. Pierceall, Anjan Thakurta, Anita Gandhi, Charlotte Pawlyn, Sarah R. Brown, Martin Kaiser   +14 more
wiley   +1 more source

An intracellular recombinant single‐chain variable antibody fragment as a new class of phosphodiesterase type 5 inhibitors

British Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz, Sophie Sprenger, Olga Schweigert, Sanika Mohagaonkar, Matti Walsdorff, Tanja Zeller, Filip Berisha, Viacheslav O. Nikolaev, Sergei D. Rybalkin   +8 more
wiley   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Retreatment with talquetamab and pomalidomide in triple‐class–BCMA–GPRC5D refractory myeloma

British Journal of Haematology, EarlyView.
Kian J. Rahbari, Gliceida M. Galarza Fortuna, Bhagirathbhai Dholaria, Douglas W. Sborov, Muhamed Baljevic   +4 more
wiley   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Elevated desmoglein‐2 expression in multiple myeloma is a prognostic marker across genomic subtypes with impact on high‐risk cytogenetics and a distinct gene expression profile

British Journal of Haematology, EarlyView.
Barbara J. McClure, John Toubia, Charlotte E. J. Toomes, O. Giles Best, Angelina Yong, Cindy H. Lee, Claudine S. Bonder, Chung Hoow Kok   +7 more
wiley   +1 more source